A Phase Ia-Ib Dose-escalation Study Evaluating Safety and Efficacy of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) With Concomitant Capecitabine Chemotherapy for Resectable Carcinoma of Exocrine Pancreas.
Overview
- Phase
- Phase 1
- Intervention
- stereotactic body radiation therapy
- Conditions
- Stage IA Pancreatic Cancer
- Sponsor
- University of Wisconsin, Madison
- Enrollment
- 21
- Locations
- 1
- Primary Endpoint
- Incidence of dose-limiting toxicity defined as any grade 3-4 non-hematologic toxicity or grade 5 toxicity attributable to combination chemo-radiotherapy per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with capecitabine before surgery in treating patients with pancreatic cancer that can be removed by surgery. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving stereotactic body radiation therapy and capecitabine before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Detailed Description
PRIMARY OBJECTIVES: I. To determine the recommended-phase-II-dose (RPTD) of stereotactic body radiation therapy (SBRT) at an escalating dose schedule when combined with standard-dose capecitabine as neoadjuvant therapy for resectable carcinoma of exocrine pancreas. SECONDARY OBJECTIVES: I. To estimate the incidence of overall 30-day post-operative complications. II. To estimate the radiological response rates. III. To estimate the pathological response rates. IV. To estimate the rates of resection with negative margins. V. To estimate the recurrence free survival (RFS). VI. To estimate the overall survival (OS). TERTIARY OBJECTIVES (OPTIONAL): I. To define tumor volume (TV), dynamic contrast enhancement (DCE) pattern and mean apparent diffusion coefficient (ADC) measurements in diffusion-weighted magnetic resonance (MR) imaging (DWI) in patients with resectable pancreatic cancer undergoing neoadjuvant SBRT and concomitant chemotherapy (ChT). II. To correlate TV, DCE and ADC measurements at baseline magnetic resonance imaging (MRI) versus final pathological response. III. To correlate TV, DCE and ADC changes from baseline in MRI done three weeks post-SBRT versus final pathological response. IV. To predict surgical margin status using MRI done at baseline and at three weeks post-SBRT. V. To correlate TV, DCE and ADC changes from baseline in MRI done post-3rd fraction at baseline versus final pathological response. VI. To describe in the biopsy and/ or the surgical specimen, expression of following markers: secreted protein acidic and rich in cysteine (SPARC) expression; distribution of pancreatic stellate cells (PSC); distribution of cluster of differentiation (CD)4+/ CD8+ T cell, CD56+ natural killer (NK) cells; other molecular and inflammatory cellular markers may be explored. VII. To describe changes induced by neoadjuvant therapy by comparison of expression of these markers between the biopsy and the surgical specimen. VIII. To compare baseline and/ or post-treatment expression with treatment response, toxicity and clinical survival outcome. OUTLINE: This is a dose-escalation study of SBRT. Participants undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine orally (PO) every 12 hours 5 days a week for 2 weeks. Participants then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT. After completion of study treatment, participants are followed up at 1 month and 3 months, every 3 months for 1 year, and then every 6 months for 2 years.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmed carcinoma of exocrine pancreatic head amenable to oncological surgical resection per findings on a pancreatic-specific computed tomography (CT) or MRI scan. Tumors of the body that allow a surgical approach similar to pancreatic head tumors are acceptable.
- •Must be deemed a surgical candidate by the surgical oncology service.
- •Eastern Cooperative Oncology Group (ECOG) performance score of =\< 2
- •Signed informed consent document(s)
- •Patients with no evidence of regional or distant metastatic disease based on CT scan of the chest/ abdomen/pelvis.
- •Absolute neutrophil count (ANC) \>= 1,500 cells/mm3
- •Platelet count \>= 100,000 cells/mm3
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 times the upper limit of normal
- •Total bilirubin =\< 3 times the upper limit of normal if patient had recent biliary stenting, total bilirubin =\< 1.5 times the upper limit of normal if no biliary stenting was done
- •Serum creatinine within normal range with a creatinine clearance \>= 30 ml/min
Exclusion Criteria
- •Patients with primary ampullary, biliary or duodenal cancer would be excluded
- •Patients with tumors primarily of the body or tail of the pancreas requiring a distal pancreaticoduodenectomy would be excluded
- •(H/ o) Crohn's disease/ ulcerative colitis/ scleroderma
- •History of prior allergic reactions attributed to compounds of similar chemical or biologic composition as capecitabine
- •History of prior allergic reactions attributed to compounds of CT/ MRI contrast that cannot be managed with appropriate pre-medication prophylaxis and thereby preclude use of baseline/ follow-up or radiation planning imaging
- •Any prior external beam radiation will be evaluated to determine radiation field overlaps and appropriateness of protocol radiation, any invasive cancer in the last 5 years (except for a diagnosis of low-risk prostate cancer, treated non-melanoma/melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast and appropriately treated in-situ/early stage cervical/endometrial cancer)
- •Pregnant or nursing women; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the point of study entry and for the duration of all active treatments; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- •Treatment with a non-approved or investigational drug within 28 days of study treatment
- •History of having MRI non-compatible metal (injury- or treatment-related) in the body will be an exclusion criteria specific to the MRI sub-study
- •Considering the small size of the PET/MR scanner bore, subjects with known severe claustrophobia or with body habitus not compatible with the bore (\>300lbs, BMI\>40) may also have to be excluded.
Arms & Interventions
Treatment (SBRT, capecitabine, and surgery)
Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
Intervention: stereotactic body radiation therapy
Treatment (SBRT, capecitabine, and surgery)
Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
Intervention: capecitabine
Treatment (SBRT, capecitabine, and surgery)
Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
Intervention: therapeutic conventional surgery
Treatment (SBRT, capecitabine, and surgery)
Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
Intervention: magnetic resonance imaging
Treatment (SBRT, capecitabine, and surgery)
Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
Intervention: laboratory biomarker analysis
Outcomes
Primary Outcomes
Incidence of dose-limiting toxicity defined as any grade 3-4 non-hematologic toxicity or grade 5 toxicity attributable to combination chemo-radiotherapy per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Time Frame: Up to 90 days from the start of SBRT and capecitabine
The number and percent of patients reporting adverse events (all, severe or worse, serious and related) will be quantified for each dose level.
Secondary Outcomes
- Pathological response, graded based on the College of American Pathologists (CAP) and Ishikawa, Evans, and Chun grading systems(Up to 3 years)
- Radiological response per Response Evaluation Criteria in Solid Tumors (RECIST) and volumetric measurements(Up to 3 years)
- Incidence of 30-day post-operative complications(30 days)
- Incidence of margin-negative resection, defined as the absence of viable tumor cells at the inked surgical margin(Up to 3 years)
- Loco-regional recurrence free survival, defined with follow-up radiological assessment(From the point of start of SBRT to the point of recurrence or death, assessed up to 3 years)
- OS(From the point of start of SBRT to the time of death or last follow-up if alive, assessed up to 3 years)